AstraZeneca to manufacture cancer killer in Singapore
AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.
AstraZeneca says it will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs).
The biopharmaceutical giant announced on Monday.
AstraZeneca aimed to start designing and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.
According to the company ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.